Press Releases
Please, enter cell line, author or any other phrase or word you would like to search for.
TO 3 Warrants Subscribed to 100 %
On 2 May 2023, the exercise period for warrants of series TO 3, which were issued in connection with PHI AB’s rights issue of units that were announced on 22 February 2022, ended. […] The proceeds of the TO 3 warrants amount to approximately SEK 12.7 million before the deduction of transaction-related costs, corresponding to a subscription rate of 100 percent.
Last day of trading in warrants of series TO 3 is 27 April 2023
Thursday, 27 April 2023, is the last day of trading in warrants of series TO 3, which were issued in connection with PHI’s rights issue of units that was announced on 22 February 2022. The exercise period runs until and including 2 May 2023.
Insider Acquisitions in Phase Holographic Imaging
CEO Patrik Eschricht, chairman Peter Egelberg and deputy board member Ann Christine Egelberg has recently acquired additional holdings in Phase Holographic Imaging.
PHI enters into underwriting commitment with Altium in ongoing exercise of TO 3 warrants
PHI announces that the Company’s largest shareholder Altium and PHI has agreed on an underwriting commitment free-of-charge in the ongoing exercise of warrants of series TO 3.
Altium S.A. exercised all their obtained warrants TO 3
PHI announces that Altium S.A. exercised all their obtained warrants TO 3.
The exercise period for warrants of series TO 3 begins today
PHI announces that the exercise period for warrants of series TO 3 begins today.
The subscription price for warrants of series TO 3 has been set at SEK 3.78 per share
PHI announces that the subscription price for warrants of series TO 3 has been set at SEK 3.78 per share.
Clarification Regarding Potential Collaborations
Thi information is provided to mitigate any misinterpretation of the information unintentionally made publicly after a PHI presentation at a CERN Knowledge Transfer Seminar held on March 27, 2023.
Notice that Interim Report 3 2022/23 will be published already on March 28, 2023
PHI changes the date for publication of Interim Report 3 2022/23 to March 28, 2023.
PHI creates a subsidiary for the anticipated EU patent concerning synthetic antibodies
PHI has decided to create a dedicated subsidiary to house the synthetic antibody patent family and facilitate its business potential.